Drug Prescribing in Renal Failure: Dosing Guidelines for Adults (Q34708717)

4 August 2017

1 reference

title

Drug prescribing in renal failure: dosing guidelines for adults (English)

1 reference

4 August 2017

Drug Prescribing in Renal Failure: Dosing Guidelines for Adults (English)

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

6 October 2023

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

6 October 2023

author name string

W. M. Bennett

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6356890

6 October 2023

G. R. Aronoff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6356890

6 October 2023

G. Morrison

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6356890

6 October 2023

T. A. Golper

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6356890

6 October 2023

J. Pulliam

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6356890

6 October 2023

M. Wolfson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6356890

6 October 2023

I. Singer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6356890

6 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6356890

6 October 2023

publication date

1 November 1983

1 reference

full work available at URL

4 August 2017

https://api.elsevier.com/content/article/PII:S0272638683800602?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

https://api.elsevier.com/content/article/PII:S0272638683800602?httpAccept=text/plain

6 October 2023

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

American Journal of Kidney Diseases

6 October 2023

published in

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

155-193

1 reference

Drug therapy in renal failure: dosing guidelines for adults. Part I: Antimicrobial agents, analgesics

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nomograms for drug use in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Impaired Binding of Drugs and Endogenous Ligands in Renal Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Protein binding displacement interactions and their clinical importance

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug therapy in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of drug overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug interferences with clinical laboratory tests

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug metabolites in renal failure: pharmacokinetic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Stability of antimicrobial agents in peritoneal dialysate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Antifungal Agents Used in Systemic Mycoses Activity and Therapeutic Use

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Flucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and Clearance

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Flucytosine kinetics in subjects with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Disposition of ketoconazole, an oral antifungal, in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Tuberculosis in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Rifampicin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Metabolism and pharmacokinetics of the antibiotic rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug therapy: antiviral agents (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal function after acyclovir intravenous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Amantadine hydrochloride pharmacokinetics in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Influence of age and renal disease on aminoglycoside dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Amikacin serum concentrations: prediction of levels and dosage guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Inactivation of amikacin and gentamicin by carbenicillin in patients with end-stage renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of gentamicin in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Gentamicin inactivation by piperacillin or carbenicillin in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of netilmicin in patients with renal impairment and in patients on dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

The in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of cefadroxil in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of Cefamandole in Patients with Renal Impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cefamandole kinetics in uremic patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of cefazolin in patients with renal failure; special reference to hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Ceftizoxime kinetics and renal handling

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Elimination kinetics of ceftizoxime in humans with and without renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of Cephalothin on Measurement of Creatinine Concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of Hemodialysis and Renal Failure on Serum and Urine Concentrations of Cephapirin Sodium

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The administration of cephradine to patients in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal function during cefoperazone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Ceforanide kinetics in renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Cefotaxime in Patients with Normal and Reduced Renal Function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The Pharmacokinetics of Cefotaxime and Its Metabolites in Subjects with Normal and Impaired Renal Function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cefoxitin disposition during peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of Cefroxadine in Healthy Volunteers and Patients with Impaired Renal Function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cefsulodin kinetics in renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of moxalactam in patients with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Moxalactam pharmacokinetics during hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Moxalactam kinetics in hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Serum and plasma concentrations of clindamycin following a single intramuscular injection of clindamycin phosphate in maintenance haemodialysis patients and normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmakokinetics of Erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of intravenous erythromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of Peritoneal Dialysis on Serum Levels of Tobramycin and Clindamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Drug therapy: metronidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Concentration of Metronidazole in Serum during Peritoneal Dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Severe Metabolic Acidosis Associated with Nalidixic Acid Overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nalidixic acid kinetics after single and repeated oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nitrofurantoin polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Kinetics of intravenous amoxicillin in patients on long-term dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of Amoxicillin: Dosage Nomogram for Patients with Impaired Renal Function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Diagnosis and treatment: drugs five years later. Amoxicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Intravenous azlocillin kinetics in patients on long-term hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of azlocillin in subjects with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Carbenicillin therapy in patients with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Carbenicillin-induced coagulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of Ticarcillin in Patients with Abnormal Renal Function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Mezlocillin dose dependent elimination kinetics in renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The effect of piperacillin dose on elimination kinetics in renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of piperacillin in subjects with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Serum and urinary concentrations of cyclacillin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Dicloxacillin and cloxacillin: Pharmacokinetics in healthy and hemodialysis subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal failure, hemodialysis, and nafcillin kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of Trimethoprim-Sulfamethoxazole on the Renal Excretion of Creatinine in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Minocycline: A review of its antibacterial and pharmacokinetic properties and therapeutic use

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Minocycline and doxycycline kinetics in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Peritoneal Transport of Vancomycin during Peritoneal Dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Narcotic Analgesics in Anuric Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Disposition of narcotics in patients with renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug Intoxication and Neurological Episodes in Chronic Renal Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug-induced encephalopathy in patients on maintenance haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Management of salicylate intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of Salicylate in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Kinetics of salicylate elimination by anephric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Clinical pharmacokinetics of paracetamol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Disposition of zomepirac sodium in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Butorphanol: a review of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug therapy: butorphanol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Fentanyl Pharmacokinetics in Awake Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Methadone use in patients with chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of pethidine: 1982.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Meperidine disposition in man: Influence of urinary pH and route of administration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The Metabolism of Morphine and Heroin in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Morphine and phenytoin binding to plasma proteins in renal and hepatic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The clinical pharmacology of pentazocine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of hemodialysis on propoxyphene and norpropoxyphene concentrations in blood of anephric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Hypnotics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Psychotherapeutic agents in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pentobarbital elimination in patients with poor renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of Haemoperfusion for Drug Overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Chlordiazepoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Comparative protein binding of diazepam and desmethyldiazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Diazepam and lidocaine plasma protein binding in renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Protein binding of diazepam and digitoxin in uremic and normal serum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Prazepam and Lorazepam, Two New Benzodiazepines

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Impaired elimination of lorazepam following subchronic administration in two patients with renal failure [letter]

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Biotransformation and excretion of lorazepam in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Oxazepam and Lorazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal disease, age, and oxazepam kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Resin Hemoperfusion for Treatment of Ethchlorvynol Overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Glutethimide poisoning. A metabolite contributes to morbidity and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal function and biopsy findings in patients on long-term lithium treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nephrotic syndrome secondary to lithium therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Chronic renal lesions following long-term treatment with lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Hazards and adverse effects of lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effects of lithium on the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Lithium therapy during maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Mania during maintenance hemodialysis successfully treated with oral lithium carbonate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Inter- and intra-individual variation in the metabolism of methaqualone in man after a single oral dose

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The clinical application of tricyclic antidepressant pharmacokinetics and plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nortriptyline metabolism in chronic renal failure: metabolite elimination

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Active metabolites of imipramine and desipramine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Protriptyline kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

New antiarrhythmic drugs: their place in therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Comparative pharmacokinetics of new antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of intravenous and oral bretylium tosylate in survivors of ventricular tachycardia or fibrillation: clinical application of a new assay for bretylium

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of oral disopyramide phosphate in patients with renal impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Disposition kinetics of disopyramide in patients with renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Lidocaine Pharmacokinetics in Advanced Heart Failure, Liver Disease, and Renal Failure in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetic Principles of Lidocaine Dosing in Relation to Disease State

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Kinetics of procainamide and N-acetylprocainamide in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Quinidine Pharmacokinetics in Continuous Abulatory Peritoneal Dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Digitoxin elimination reduced during quinidine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Digoxin-quinidine interaction in patients with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Decreased quinidine plasma protein binding during hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of quinidine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Adverse effects of antihypertensive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Correlation of Pharmacological Effects with Plasma Levels of Antihypertensive Drugs in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of β-Adrenoreceptor Blocking Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Immune-complex glomerulopathy in patients treated with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effects of captopril on renal function in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clonidine kinetics in man‐evidence for dose dependency and changed pharmacokinetics during chronic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clonidine hydrochloride: review of pharmacologic and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drugs five years later: clonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Disposition of guanethidine during chronic oral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Effects of methyldopa on renal hemodynamics and tubular function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Diazoxide concentration-response relation in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Decreased plasma protein binding of diazoxide in uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics and Response to Diazoxide in Renal Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Variability of plasma hydralazine concentrations in male hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Kinetics of hydralazine and its main metabolites in slow and fast acetylators

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Plasma concentration and acetylator phenotype determine response to oral hydralazine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Efficacy of minoxidil in the treatment of severe hypertension in systemic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Minoxidil: a review of its pharmacological properties and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Pharmacology and Pharmacokinetics of Minoxidil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal function during long-term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Minoxidil and pericardial effusion: an idiosyncratic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal effects of nitroprusside and hydralazine in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug therapy. Prazosin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Prazosin kinetics and effectiveness in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Prazosin Update A Review of its Pharmacological Properties and Therapeutic Use in Hypertension and Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Excretion and metabolism of reserpine in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

beta-Adrenoceptor antagonists: new drugs and new indications

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

??-Blockers and Renal Function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of atenolol--a review

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Atenolol kinetics in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Antenolol: A Long-Acting Beta_1-Adrenoceptor Antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Metoprolol kinetics and dose response in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The pharmacokinetics of metoprolol and its metabolites in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Beta blockade with pindolol: Differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pindolol: effects on blood pressure and plasma renin activity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effects of pindolol on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of propranolol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of dose and uremia on plasma and urine profiles of propranolol metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Massive propranolol metabolite retention during maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Propranolol disposition in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nadolol: a new beta-adrenoceptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug therapy: atenolol and timolol, two new systemic beta-adrenoceptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Therapeutic importance of calcium antagonists in coronary artery diseases and congestive heart failure: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Calcium Antagonists Pharmacokinetic Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Serum binding of diltiazem in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Diltiazem: a review of its clinical efficacy and use.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The pharmacokinetics of diltiazem in healthy American men

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nifedipine and beta-blocker drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nifedipine and propranolol: a beneficial drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The Pharmacology of Verapamil. III. Pharmacokinetics in Normal Subjects After Intravenous Drug Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Verapamil protein binding in patients and in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Digoxin-verapamil interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Digitoxin-quinidine interaction: pharmacokinetic evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Interindividual differences in the pharmacokinetics of digitoxin and digoxin during long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of digoxin 1980.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Digoxin-quinidine interaction in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Loading dose of digoxin in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of Metildigoxin and Digoxin in Geriatric Patients with Normal and Elevated Serum Creatinine Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Digoxin dosage in renal insufficiency: impracticality of basing it on the creatinine clearance, body weight and volume of distribution

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Digoxin pharmacokinetics in continuous peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Impaired Intestinal Digoxin Absorption in Experimental Chronic Uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of diuretics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Amiloride handling in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Electrolyte Excretion Patterns. Intravenous and Oral Doses of Bumetanide Compared to Furosemide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Transient and permanent deafness following treatment with ethacrynic acid in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Elimination of furosemide in healthy subjects and in those with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics/pharmacodynamics of furosemide in man: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Variability in derived parameters of furosemide pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Frusemide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effects of Frusemide in Chronic Renal Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Plasma and urinary levels of triamterene and certain metabolites after oral administration to man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Delayed elimination of triamterene and its active metabolite in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Triamterene and renal stone formation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Spironolactone: Disposition, Metabolism, Pharmacodynamics, and Bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Dose-response relationships for spironolactone at steady state

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nitroglycerin and long-acting nitrates

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Fate of isosorbide dinitrate and mononitrates in patients with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Isosorbide dinitrate: pharmacokinetics after intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effects and pharmacokinetics of isosorbide dinitrate in normal man.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Current concepts: guidelines for the use of thrombolytic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Heparin half-life in normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Oral Anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Warfarin elimination and responsiveness in patients with renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The use of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Plasma Protein Binding of Phenytoin and Warfarin in Patients Undergoing Renal Transplantation1

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of primidone elimination by uremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Protein binding of valproic acid in uremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of diphenhydramine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Metabolic disposition of diphenhydramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of commonly used anticancer drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Antineoplastic drugs: clinical pharmacology and therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The metabolism of azathioprine in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Busulphan Haemorrhagic Cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Acute nephrotoxicity following cis-dichlorodiammine-platinum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal and electrolyte disturbances associated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Long term effect of Cis-Diamminedichloride platinum (CDDP) on renal function and structure in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The Role of cis-Platinum in Solid-Tumor Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The renal pathology in clinical trials of cis-platinum (II) diamminedichloride

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Kinetics of cis-dichlorodiammineplatinum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cisplatin pharmacokinetics in a patient with renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Hypomagnesemia and Renal Magnesium Wasting in Patients Receiving Cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cyclophosphamide dose in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Haemodialysis during cyclophosphamide treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacology of l-β-D-arabinofuranosyl cytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Kinetics of intravenous melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Hemoperfusion for methotrexate removal

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Methotrexate and hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal function and the rate of disappearance of methotrexate from serum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Methotrexate1

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Metabolic and toxic effects of mithramycin during tumor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal disease after mitomycin C therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Chronic Renal Failure in Children Treated with Methyl CCNU

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Acute renal failure and renal tubular squamous metaplasia following treatment with streptozotocin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nephrotoxicity of streptozocin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The pharmacokinetics of [3H]-vincristine in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Reduction of renal function by newer nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Nonsteroidal Anti-Inflammatory Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug therapy: nonsteroidal antiinflammatory drugs (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Allopurinol-induced interstitial nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Benoxaprofen kinetics in renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Colchicine plasma levels. Implications as to pharmacology and mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Acute renal failure associated with diflunisal

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Monitoring Gold Plasma Levels in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetic modelling of ibuprofen

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

1 reference

7 January 2021

Indomethacin-associated acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Protein binding of indomethacin: binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate, in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of naproxen in subjects with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Naproxen-probenecid interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Disposition and oxidative metabolism of phenylbutazone in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Phenylbutazone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Acute nephrotic syndrome with reversible renal failure after phenylbutazone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The metabolism of probenecid in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Sulphinpyrazone-induced acute renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Sulfinpyrazone kinetics after intravenous and oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The disposition of sulindac

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetic studies of tolmetin in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Prednisone and prednisolone bioavailability in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Metabolism of adrenocorticosteroids in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Prednisone and Prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of hemodialysis on methylprednisolone plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical pharmacology of oral antidiabetic agents (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The pharmacology of sulfonylureas

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of acetohexamide (a sulfonylurea hypoglycemic agent) in blood plasma on creatinine assay in clinical laboratory tests

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Binding of Sulfonylureas to Serum Proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics and biotransformation of chlorpropamide in man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

125I-insulin metabolism in chronic renal failure treated by renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of Renal Disease on Renal Uptake and Excretion of Insulin in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Carbohydrate metabolism in uremia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Cholestyramine in uraemic pruritus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Control of clofibrate toxicity in uremic hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Hypolipidaemic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clofibrate-Induced Antidiuresis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Chronic clofibrate therapy in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Treatment of hyperlipidaemia in patients on chronic haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of edrophonium in anephric and renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Antagonism of pancuronium in renal failure: no recurarization

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of pancuronium in patients with normal and impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal failure and postoperative respiratory failure: recurarization?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal Function and the Pharmacokinetics of Neostigmine in Anesthetized Man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Renal Clearance of Pyridostigmine in Patients with Myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pyridostigmine kinetics with and without renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Gallamine disposition in surgical patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Amantadine Toxicity in a Patient with Renal Insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Elimination of oral cimetidine in chronic renal failure and during haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of cimetidine on renal function in normal man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Drug therapy: Cimetidine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Therapeutic effect of cimetidine in patients undergoing haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Oral absorption of cimetidine and its clearance in patients with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Steady-state kinetics and dosage requirements of cimetidine in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

The pharmacokinetics of single doses of metoclopramide in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Metoclopramide. An updated review of its pharmacological properties and clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Metabolism of 35S-labelled antithyroid drugs in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Monitoring Serum Theophylline Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Intravenous theophylline therapy: nomogram guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Effect of hemodialysis on the pharmacokinetics of theophylline in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Hemodialysis of Theophylline in Uremic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2883%2980060-2

7 January 2021

Clinical Pharmacokinetics of Isoniazid

31

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Amantadine hydrochloride pharmacokinetics in patients with impaired renal function

6 October 2023

40

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Cefadroxil kinetics in patients with renal insufficiency

6 October 2023

59

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Cephalothin handling in patients undergoing hemodialysis

6 October 2023

68

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Pharmacokinetics of intravenous and intraperitoneal cefuroxime during peritoneal dialysis

6 October 2023

85

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Cefsulodin pharmacokinetics during hemodialysis

6 October 2023

88

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency

6 October 2023

93

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Effect of hemodialysis on total body clearance of chloramphenicol

6 October 2023

94

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

The Pharmacokinetics of Nitrofurantoin and its Related Bioavailability

6 October 2023

107

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis

6 October 2023

136

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

6 October 2023

Newer potent analgesics

143

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Persistence of morphine in blood in association with hepatic necrosis and renal tubular necrosis

6 October 2023

150

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

6 October 2023

Drugs for schizophrenia

181

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Studies on serum protein binding of haloperidol

6 October 2023

200

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Structural and functional effects of long-term lithium therapy

6 October 2023

208

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Impairment of renal function in patients on long-term lithium treatment

6 October 2023

209

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Monoamine oxidase inhibitors for depression

6 October 2023

211

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

The pharmacology and therapeutic application of the phenothiazines

6 October 2023

215

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Hazards of phenothiazines in chronic renal failure

6 October 2023

216

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

6 October 2023

Drugs Five Years Later

265

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Pharmacokinetics of Clonidine

6 October 2023

266

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Pharmacology of Clonidine

6 October 2023

267

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Discontinuation Syndrome Following Cessation of Treatment with Clonidine and Other Antihypertensive Agents

6 October 2023

268

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Clinical pharmacokinetics of methyldopa

6 October 2023

274

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

The biological fate of reserpine

6 October 2023

293

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Calcium Blocking Drugs for Angina Pectoris

6 October 2023

321

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Comparison of methods for estimating digoxin dosing regimens: further analysis

6 October 2023

339

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Efficacy and Safety of Metolazone in Renal Failure and the Nephrotic Syndrome

6 October 2023

359

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Renal and systemic acid-base effects of chronic spironolactone administration

6 October 2023

366

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Hemodialysis clearance of ethosuximide in patients with chronic renal disease

6 October 2023

385

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Metabolism of chlorpheniramine maleate in man

6 October 2023

391

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function

6 October 2023

394

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Comparative mammalian metabolism of adriamycin and daunorubicin

6 October 2023

397

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure

6 October 2023

402

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus

6 October 2023

404

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Enhanced bleomycin toxicity during acute renal failure

6 October 2023

407

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Hemodialysis in cancer chemotherapy

6 October 2023

426

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Pharmacokinetics of fluorouracil in humans

6 October 2023

427

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Toxicology and pharmacology of the nitrosoureas

6 October 2023

441

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Pharmacokinetics and metabolism of vinblastine in humans

6 October 2023

445

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Elimination and serum protein binding of phenylbutazone in patients with renal insufficiency

6 October 2023

475

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Prolonged serum half-life of cortisol in renal failure

6 October 2023

487

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Clofibrate treatment of hyperlipidemia in chronic renal failure

6 October 2023

508

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

The Effect of Cimetidine, a New Histamine H2-Receptor Antagonist, on Renal Function

6 October 2023

538

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

Nephropathy Induced by D-Penicillamine

6 October 2023

548

1 reference

https://api.crossref.org/works/10.1016/S0272-6386(83)80060-2

6 October 2023

Identifiers

1 reference

4 August 2017

1 reference